Abstract
Summary
RNA interference is a relatively new concept in the field of medicine. It is a process in which the ribonucleic acid inhibits translation or gene expression by converting single-stranded mRNA to double stranded RNA, thereby neutralizing the target nucleic acids.
LPI (LP Information)' newest research report, the “RNAi Technology Industry Forecast” looks at past sales and reviews total world RNAi Technology sales in 2022, providing a comprehensive analysis by region and market sector of projected RNAi Technology sales for 2023 through 2029. With RNAi Technology sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNAi Technology industry.
This Insight Report provides a comprehensive analysis of the global RNAi Technology landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RNAi Technology portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNAi Technology market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNAi Technology and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNAi Technology.
The global RNAi Technology market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for RNAi Technology is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for RNAi Technology is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for RNAi Technology is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key RNAi Technology players cover Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Quark Pharmaceuticals, Inc., Arbutus Biopharma, Benitec Biopharma, Calando and Silence Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of RNAi Technology market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Cancer
Liver Disorders
Respiratory Disorders
Neurological Disorders
Autoimmune Disorders
Others
Segmentation by application
Drug Discovery & Development
Therapeutics
Drug Delivery
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alnylam Pharmaceuticals
Dicerna Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc.
Arbutus Biopharma
Benitec Biopharma
Calando
Silence Therapeutics
Gotham Therapeutics
LPI (LP Information)' newest research report, the “RNAi Technology Industry Forecast” looks at past sales and reviews total world RNAi Technology sales in 2022, providing a comprehensive analysis by region and market sector of projected RNAi Technology sales for 2023 through 2029. With RNAi Technology sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNAi Technology industry.
This Insight Report provides a comprehensive analysis of the global RNAi Technology landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RNAi Technology portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNAi Technology market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNAi Technology and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNAi Technology.
The global RNAi Technology market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for RNAi Technology is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for RNAi Technology is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for RNAi Technology is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key RNAi Technology players cover Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Quark Pharmaceuticals, Inc., Arbutus Biopharma, Benitec Biopharma, Calando and Silence Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of RNAi Technology market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Cancer
Liver Disorders
Respiratory Disorders
Neurological Disorders
Autoimmune Disorders
Others
Segmentation by application
Drug Discovery & Development
Therapeutics
Drug Delivery
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alnylam Pharmaceuticals
Dicerna Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc.
Arbutus Biopharma
Benitec Biopharma
Calando
Silence Therapeutics
Gotham Therapeutics
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global RNAi Technology Market Size 2018-2029
2.1.2 RNAi Technology Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 RNAi Technology Segment by Type
2.2.1 Cancer
2.2.2 Liver Disorders
2.2.3 Respiratory Disorders
2.2.4 Neurological Disorders
2.2.5 Autoimmune Disorders
2.2.6 Others
2.3 RNAi Technology Market Size by Type
2.3.1 RNAi Technology Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global RNAi Technology Market Size Market Share by Type (2018-2023)
2.4 RNAi Technology Segment by Application
2.4.1 Drug Discovery & Development
2.4.2 Therapeutics
2.4.3 Drug Delivery
2.4.4 Others
2.5 RNAi Technology Market Size by Application
2.5.1 RNAi Technology Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global RNAi Technology Market Size Market Share by Application (2018-2023)
3 RNAi Technology Market Size by Player
3.1 RNAi Technology Market Size Market Share by Players
3.1.1 Global RNAi Technology Revenue by Players (2018-2023)
3.1.2 Global RNAi Technology Revenue Market Share by Players (2018-2023)
3.2 Global RNAi Technology Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 RNAi Technology by Regions
4.1 RNAi Technology Market Size by Regions (2018-2023)
4.2 Americas RNAi Technology Market Size Growth (2018-2023)
4.3 APAC RNAi Technology Market Size Growth (2018-2023)
4.4 Europe RNAi Technology Market Size Growth (2018-2023)
4.5 Middle East & Africa RNAi Technology Market Size Growth (2018-2023)
5 Americas
5.1 Americas RNAi Technology Market Size by Country (2018-2023)
5.2 Americas RNAi Technology Market Size by Type (2018-2023)
5.3 Americas RNAi Technology Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNAi Technology Market Size by Region (2018-2023)
6.2 APAC RNAi Technology Market Size by Type (2018-2023)
6.3 APAC RNAi Technology Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe RNAi Technology by Country (2018-2023)
7.2 Europe RNAi Technology Market Size by Type (2018-2023)
7.3 Europe RNAi Technology Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa RNAi Technology by Region (2018-2023)
8.2 Middle East & Africa RNAi Technology Market Size by Type (2018-2023)
8.3 Middle East & Africa RNAi Technology Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global RNAi Technology Market Forecast
10.1 Global RNAi Technology Forecast by Regions (2024-2029)
10.1.1 Global RNAi Technology Forecast by Regions (2024-2029)
10.1.2 Americas RNAi Technology Forecast
10.1.3 APAC RNAi Technology Forecast
10.1.4 Europe RNAi Technology Forecast
10.1.5 Middle East & Africa RNAi Technology Forecast
10.2 Americas RNAi Technology Forecast by Country (2024-2029)
10.2.1 United States RNAi Technology Market Forecast
10.2.2 Canada RNAi Technology Market Forecast
10.2.3 Mexico RNAi Technology Market Forecast
10.2.4 Brazil RNAi Technology Market Forecast
10.3 APAC RNAi Technology Forecast by Region (2024-2029)
10.3.1 China RNAi Technology Market Forecast
10.3.2 Japan RNAi Technology Market Forecast
10.3.3 Korea RNAi Technology Market Forecast
10.3.4 Southeast Asia RNAi Technology Market Forecast
10.3.5 India RNAi Technology Market Forecast
10.3.6 Australia RNAi Technology Market Forecast
10.4 Europe RNAi Technology Forecast by Country (2024-2029)
10.4.1 Germany RNAi Technology Market Forecast
10.4.2 France RNAi Technology Market Forecast
10.4.3 UK RNAi Technology Market Forecast
10.4.4 Italy RNAi Technology Market Forecast
10.4.5 Russia RNAi Technology Market Forecast
10.5 Middle East & Africa RNAi Technology Forecast by Region (2024-2029)
10.5.1 Egypt RNAi Technology Market Forecast
10.5.2 South Africa RNAi Technology Market Forecast
10.5.3 Israel RNAi Technology Market Forecast
10.5.4 Turkey RNAi Technology Market Forecast
10.5.5 GCC Countries RNAi Technology Market Forecast
10.6 Global RNAi Technology Forecast by Type (2024-2029)
10.7 Global RNAi Technology Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Alnylam Pharmaceuticals
11.1.1 Alnylam Pharmaceuticals Company Information
11.1.2 Alnylam Pharmaceuticals RNAi Technology Product Offered
11.1.3 Alnylam Pharmaceuticals RNAi Technology Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Alnylam Pharmaceuticals Main Business Overview
11.1.5 Alnylam Pharmaceuticals Latest Developments
11.2 Dicerna Pharmaceuticals, Inc.
11.2.1 Dicerna Pharmaceuticals, Inc. Company Information
11.2.2 Dicerna Pharmaceuticals, Inc. RNAi Technology Product Offered
11.2.3 Dicerna Pharmaceuticals, Inc. RNAi Technology Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Dicerna Pharmaceuticals, Inc. Main Business Overview
11.2.5 Dicerna Pharmaceuticals, Inc. Latest Developments
11.3 Arrowhead Pharmaceuticals, Inc.
11.3.1 Arrowhead Pharmaceuticals, Inc. Company Information
11.3.2 Arrowhead Pharmaceuticals, Inc. RNAi Technology Product Offered
11.3.3 Arrowhead Pharmaceuticals, Inc. RNAi Technology Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Arrowhead Pharmaceuticals, Inc. Main Business Overview
11.3.5 Arrowhead Pharmaceuticals, Inc. Latest Developments
11.4 Ionis Pharmaceuticals, Inc.
11.4.1 Ionis Pharmaceuticals, Inc. Company Information
11.4.2 Ionis Pharmaceuticals, Inc. RNAi Technology Product Offered
11.4.3 Ionis Pharmaceuticals, Inc. RNAi Technology Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Ionis Pharmaceuticals, Inc. Main Business Overview
11.4.5 Ionis Pharmaceuticals, Inc. Latest Developments
11.5 Quark Pharmaceuticals, Inc.
11.5.1 Quark Pharmaceuticals, Inc. Company Information
11.5.2 Quark Pharmaceuticals, Inc. RNAi Technology Product Offered
11.5.3 Quark Pharmaceuticals, Inc. RNAi Technology Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Quark Pharmaceuticals, Inc. Main Business Overview
11.5.5 Quark Pharmaceuticals, Inc. Latest Developments
11.6 Arbutus Biopharma
11.6.1 Arbutus Biopharma Company Information
11.6.2 Arbutus Biopharma RNAi Technology Product Offered
11.6.3 Arbutus Biopharma RNAi Technology Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Arbutus Biopharma Main Business Overview
11.6.5 Arbutus Biopharma Latest Developments
11.7 Benitec Biopharma
11.7.1 Benitec Biopharma Company Information
11.7.2 Benitec Biopharma RNAi Technology Product Offered
11.7.3 Benitec Biopharma RNAi Technology Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Benitec Biopharma Main Business Overview
11.7.5 Benitec Biopharma Latest Developments
11.8 Calando
11.8.1 Calando Company Information
11.8.2 Calando RNAi Technology Product Offered
11.8.3 Calando RNAi Technology Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Calando Main Business Overview
11.8.5 Calando Latest Developments
11.9 Silence Therapeutics
11.9.1 Silence Therapeutics Company Information
11.9.2 Silence Therapeutics RNAi Technology Product Offered
11.9.3 Silence Therapeutics RNAi Technology Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Silence Therapeutics Main Business Overview
11.9.5 Silence Therapeutics Latest Developments
11.10 Gotham Therapeutics
11.10.1 Gotham Therapeutics Company Information
11.10.2 Gotham Therapeutics RNAi Technology Product Offered
11.10.3 Gotham Therapeutics RNAi Technology Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Gotham Therapeutics Main Business Overview
11.10.5 Gotham Therapeutics Latest Developments
12 Research Findings and Conclusion